The filing for a mixed shelf offering suggests that Sage Therapeutics is preparing to raise capital, which could be used for future projects or operational needs. However, the lack of disclosure on the size of the offering leaves uncertainty about the scale of the impact. This type of financial maneuver is common and does not necessarily indicate immediate positive or negative changes in stock price, hence a neutral short-term impact.